Nerandomilast Shows Potential Mortality Benefit in IPF Despite Neutral Composite Secondary Endpoints: Insights from FIBRONEER-IPF Extended Follow-up
Posted inInternal Medicine news Respiratory

Nerandomilast Shows Potential Mortality Benefit in IPF Despite Neutral Composite Secondary Endpoints: Insights from FIBRONEER-IPF Extended Follow-up

Long-term data from the FIBRONEER-IPF trial indicates that while nerandomilast did not significantly impact composite respiratory events, the 18 mg dose suggests a numerical reduction in mortality and maintains a favorable safety profile for patients with idiopathic pulmonary fibrosis.
Oral Nalbuphine Significantly Reduces Cough Frequency in Patients with Idiopathic Pulmonary Fibrosis: Results from the CORAL Trial
Posted inInternal Medicine news Respiratory

Oral Nalbuphine Significantly Reduces Cough Frequency in Patients with Idiopathic Pulmonary Fibrosis: Results from the CORAL Trial

The CORAL Phase 2b trial demonstrates that oral nalbuphine extended release significantly reduces objective cough frequency and improves patient-reported symptoms in idiopathic pulmonary fibrosis, addressing a critical unmet need for managing this debilitating and often refractory symptom.